Brenus Pharma has announced the launch of an international phase I/IIa clinical trial evaluating STC-1010, a next-generation immunotherapy developed through its proprietary platform.
Selected and supported by the MATWIN Acceleration program in 2021, the MATWIN International Board identified Brenus Pharma for its strong development potential. Today, this achievement stands as a tangible example of how collaborative efforts across the French innovation ecosystem can accelerate solutions for the benefit of patients.
The study, named BreAK CRC-001, is designed for patients with advanced, unresectable, or metastatic colorectal cancer (stages IIIC and IV). Currently, these patients often rely solely on chemotherapy, which offers limited outcomes.
The trial’s primary goals are to assess safety, tolerability, and to identify early signs of efficacy. The treatment protocol combines STC-1010 with a standard chemotherapy regimen (mFOLFOX6 ± bevacizumab) and an immunomodulatory approach (low-dose GM-CSF and cyclophosphamide).
Enrollment has already started: three patients have been recruited, and the first has completed eight weeks of therapy without any adverse events attributed to the experimental drug.
In total, the study aims to include more than 80 patients, with the first interim results expected in the first half of 2026.
To access the press release, click HERE
To access Brenus Pharma’s CEO Linkedin post, click HERE
